InsiderTrades.com logo
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.
James R. Kasinger net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

James Kasinger Biography and Net Worth

General Counsel of CRISPR Therapeutics
Mr. Kasinger has served as our General Counsel and Secretary since May 2017. Prior to joining our company, Mr. Kasinger served as the General Counsel and Secretary of Moderna, Inc., a biotechnology company, from April 2014 to May 2017. Prior to these roles, Mr. Kasinger was a partner at Goodwin Procter LLP, where he represented life sciences, technology and other high-growth companies. Mr. Kasinger started his legal career at Testa, Hurwitz & Thibeault. Mr. Kasinger holds a J.D. from Boston College Law School and a B.A. from Wheaton College.

What is James R. Kasinger's net worth?

The estimated net worth of James R. Kasinger is at least $3.34 million as of March 11th, 2024. Mr. Kasinger owns 60,070 shares of CRISPR Therapeutics stock worth more than $3,342,896 as of April 24th. This net worth evaluation does not reflect any other assets that Mr. Kasinger may own. Additionally, Mr. Kasinger receives a salary of $648,930.00 as General Counsel at CRISPR Therapeutics. Learn More about James R. Kasinger's net worth.

How old is James R. Kasinger?

Mr. Kasinger is currently 50 years old. There are 4 older executives and no younger executives at CRISPR Therapeutics. The oldest executive at CRISPR Therapeutics is Dr. Matthew Porteus M.D., Ph.D., Scientific Founder & Advisory Board Member, who is 56 years old. Learn More on James R. Kasinger's age.

What is James R. Kasinger's salary?

As the General Counsel of CRISPR Therapeutics AG, Mr. Kasinger earns $648,930.00 per year. There are 2 executives that earn more than Mr. Kasinger. The highest earning executive at CRISPR Therapeutics is Dr. Samarth Kulkarni, CEO & Director, who commands a salary of $1,180,000.00 per year. Learn More on James R. Kasinger's salary.

How do I contact James R. Kasinger?

The corporate mailing address for Mr. Kasinger and other CRISPR Therapeutics executives is BAARERSTRASSE 14, ZUG V8, CH-6300. CRISPR Therapeutics can also be reached via phone at (141) 561-3277 and via email at [email protected]. Learn More on James R. Kasinger's contact information.

Has James R. Kasinger been buying or selling shares of CRISPR Therapeutics?

James R. Kasinger has not been actively trading shares of CRISPR Therapeutics within the last three months. Learn More on James R. Kasinger's trading history.

Who are CRISPR Therapeutics' active insiders?

CRISPR Therapeutics' insider roster includes Bradley Bolzon (Director), Kurt Emster (Director), Tony Ho (VP), James Kasinger (General Counsel), Lawrence Klein (COO), Samarth Kulkarni (CEO), Rodger Novak (President), and Michael Tomsicek (CFO). Learn More on CRISPR Therapeutics' active insiders.

Are insiders buying or selling shares of CRISPR Therapeutics?

In the last year, insiders at the sold shares 12 times. They sold a total of 203,992 shares worth more than $13,296,584.57. The most recent insider tranaction occured on April, 15th when CEO Samarth Kulkarni sold 19,582 shares worth more than $1,173,157.62. Insiders at CRISPR Therapeutics own 4.1% of the company. Learn More about insider trades at CRISPR Therapeutics.

Information on this page was last updated on 4/15/2024.

James R. Kasinger Insider Trading History at CRISPR Therapeutics

See Full Table

James R. Kasinger Buying and Selling Activity at CRISPR Therapeutics

This chart shows James R. Kasinger's buying and selling at CRISPR Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CRISPR Therapeutics Company Overview

CRISPR Therapeutics logo
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
Read More

Today's Range

Now: $55.65
Low: $55.50
High: $57.77

50 Day Range

MA: $72.21
Low: $55.05
High: $89.12

2 Week Range

Now: $55.65
Low: $37.55
High: $91.10

Volume

918,411 shs

Average Volume

1,814,910 shs

Market Capitalization

$4.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76
The A.I. story nobody is telling you (Read ASAP)
From TradeSmith   |   Ad
There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...
Click here to see Louis' new video for yourself.